These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 11406264)

  • 1. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic allograft nephropathy: a prospective randomised trial of cyclosporin reduction with or without mycophenolate mofetil.
    Jain S; Metcalfe M; White SA; Furness PN; Nicholson ML
    Transplant Proc; 2001 May; 33(3):2165-6. PubMed ID: 11377488
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Toward an evidence-based immunosuppression].
    Pascual J
    Nefrologia; 2001; 21(6):524-5; discussion 526-7. PubMed ID: 11881421
    [No Abstract]   [Full Text] [Related]  

  • 5. Is complete avoidance of calcineurin inhibitors or steroids now possible? Importance of patient selection and choice of regimen.
    Vincenti F
    Transplant Proc; 2001 Jun; 33(4 Suppl):11S-18S. PubMed ID: 11406263
    [No Abstract]   [Full Text] [Related]  

  • 6. Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution.
    McGrath JS; Shehata M
    Transplant Proc; 2001 May; 33(3):2193-5. PubMed ID: 11377500
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress with cyclosporine-sparing regimens.
    Grinyó JM
    Transplant Proc; 1999 Dec; 31(8A):11S-16S. PubMed ID: 10616555
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation.
    Yu L; Wang Y; Fu SJ; Cheng XJ
    Transplant Proc; 2000 Nov; 32(7):1709-10. PubMed ID: 11119902
    [No Abstract]   [Full Text] [Related]  

  • 9. Nephrotoxicity of calcineurin inhibitors: new therapeutic approaches.
    Abramowicz D; Wissing KM; Broeders N
    Transplant Proc; 2000 Feb; 32(1A Suppl):3S-5S. PubMed ID: 10686309
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug regimens affect cadaveric kidney graft survival.
    Kauffman HM; Cherikh WS; Delmonico FL
    Transplant Proc; 2001; 33(1-2):1029-30. PubMed ID: 11267176
    [No Abstract]   [Full Text] [Related]  

  • 11. Minimizing calcineurin inhibitor drugs in renal transplantation.
    Flechner SM
    Transplant Proc; 2003 May; 35(3 Suppl):118S-121S. PubMed ID: 12742481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to prevent chronic allograft nephropathy in kidney transplantation: focus on calcineurin inhibitors.
    Lo A
    Prog Transplant; 2004 Jun; 14(2):157-64. PubMed ID: 15264460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy.
    Weir MR; Ward MT; Blahut SA; Klassen DK; Cangro CB; Bartlett ST; Fink JC
    Kidney Int; 2001 Apr; 59(4):1567-73. PubMed ID: 11260422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steroid withdrawal in renal transplant recipients.
    Oppenheimer F
    Transplant Proc; 2000 Feb; 32(1A Suppl):14S-15S. PubMed ID: 10686314
    [No Abstract]   [Full Text] [Related]  

  • 15. Mycophenolate mofetil prevents the progression of chronic kidney allograft nephropathy.
    Park JH; Park JH; Yang CW; Kim YS; Kim SY; Moon IS; Koh YB; Bang BK
    Transplant Proc; 2000 Nov; 32(7):1747. PubMed ID: 11119917
    [No Abstract]   [Full Text] [Related]  

  • 16. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels.
    Suwelack B; Kobelt V; Hillebrand U; Gerhardt U; Matzkies F; Hohage H
    Transplant Proc; 2002 Aug; 34(5):1808-9. PubMed ID: 12176585
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunosuppressive treatment].
    Niaudet P
    Nephrol Ther; 2011 Dec; 7(7):592-8. PubMed ID: 22118788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation?
    Hanack U; Lorf T; Braun F; Grupp C; Sattler B; Binder L; Müller GA; Ringe B
    Transplant Proc; 1998 Aug; 30(5):2293. PubMed ID: 9723477
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term graft outcome in patients with chronic allograft dysfunction after immunosuppression modifications.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; El-Baz M; Shokeir AA; Ghoneim MA
    Ann Transplant; 2008; 13(4):46-54. PubMed ID: 19034223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
    Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.